{"id":"NCT02867761","sponsor":"University of Michigan","briefTitle":"RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative","officialTitle":"RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-29","primaryCompletion":"2021-07-07","completion":"2021-07-07","firstPosted":"2016-08-16","resultsPosted":"2022-08-30","lastUpdate":"2023-04-13"},"enrollment":780,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COPD (Chronic Obstructive Pulmonary Disease)"],"interventions":[{"type":"DRUG","name":"Indacaterol/Glycopyrrolate","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Indacaterol/Glycopyrrolate","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study hypothesis is that symptomatic current and former smokers with spirometric values within the normal range (post-bronchodilator FEV1/FVC≥0.70 and post-BD FVC ≥ 70% predicted will still derive symptomatic benefit from long-acting bronchodilator therapy even though they are excluded from current GOLD guideline recommendations.","primaryOutcome":{"measure":"Proportion (Percentage) of Individuals Who Experience a 4 Unit Improvement in St. George's Respiratory Questionnaire (SGRQ) at 12 Weeks and do Not Meet Criteria for Treatment Failure During the 12 Week Treatment Period","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Indacaterol/Glycopyrrolate","deltaMin":128,"sd":null},{"arm":"Placebo","deltaMin":144,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.65"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["36066078"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":261},"commonTop":[]}}